Who is on it, and how far along Every drug ChEMBL records acting on AKT1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved1 Capivasertib Capivasertib SponsorAstraZeneca Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials41 Phase 32 Ipatasertib Ipatasertib SponsorRoche ModalitySmall molecule ActionInhibitor Open trials21 Afuresertib Afuresertib SponsorLaekna Limited ModalitySmall molecule ActionInhibitor Open trials1 Phase 25 Miransertib Miransertib SponsorMerck & Co. (MSD) ModalitySmall molecule ActionInhibitor Open trials2 MK-2206 MK-2206 SponsorNot known ModalitySmall molecule ActionInhibitor Open trials2 Uprosertib Uprosertib SponsorNot known ModalitySmall molecule ActionInhibitor Open trials1 Pifusertib Pifusertib SponsorTaiho Oncology ModalitySmall molecule ActionNegative allosteric modulator Open trials0 Triciribine phosphate Triciribine phosphate SponsorPrescient Therapeutics, Ltd. ModalitySmall molecule ActionInhibitor Open trials0 Phase 15 GSK-690693 GSK-690693 SponsorGSK ModalitySmall molecule ActionInhibitor Open trials0 LY-2780301 LY-2780301 SponsorEli Lilly ModalityOther ActionInhibitor Open trials0 MK-2201 MK-2201 SponsorNot known ModalityOther ActionInhibitor Open trials0 TAS0612 TAS0612 SponsorTaiho Oncology ModalitySmall molecule ActionInhibitor Open trials0 XL-418 XL-418 SponsorExelixis ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 12 of 13 act as: Serine/threonine-protein kinase AKT inhibitor; the rest name their own mechanism. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing Capivasertib Phase 3 Not yet recruiting SWOG Cancer Research Network Sep 3, 2026 Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer Capivasertib Phase 1 / Phase 2 Not yet recruiting VA Office of Research and Development Aug 28, 2026 Fast-Her: Fasting Effects on Breast Cancer Treatment Capivasertib Not applicable Recruiting University of Minnesota Jun 3, 2026 Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib Capivasertib Phase 1 / Phase 2 Not yet recruiting Shanxi Province Cancer Hospital Mar 20, 2026 Rash & Diarrhea Prophylaxis With Capivasertib Capivasertib Phase 2 Recruiting Maryam Lustberg Feb 23, 2026 A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment Capivasertib Phase 1 Recruiting AstraZeneca Jan 15, 2026 CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL Capivasertib Phase 1 / Phase 2 Recruiting University of Chicago Dec 19, 2025 Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors Capivasertib Phase 1 / Phase 2 Recruiting Aminex Therapeutics, Inc. Dec 17, 2025 Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) Ipatasertib Phase 2 Active, not recruiting National Cancer Institute (NCI) May 6, 2024 A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Ipatasertib Phase 3 Recruiting Hoffmann-La Roche May 17, 2023 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Ipatasertib Phase 2 Recruiting National Cancer Institute (NCI) Oct 3, 2022 Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial Ipatasertib Phase 2 Active, not recruiting National Cancer Institute (NCI) Sep 26, 2022 Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers Ipatasertib Phase 1 / Phase 2 Active, not recruiting National Cancer Institute (NCI) Sep 14, 2022 Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC Ipatasertib Phase 2 Active, not recruiting Queen Mary University of London Aug 12, 2022 Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) Ipatasertib Phase 2 Recruiting German Cancer Research Center Apr 18, 2022 Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Ipatasertib Phase 1 Active, not recruiting National Cancer Institute (NCI) Mar 14, 2022 A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) Miransertib Phase 2 Active, not recruiting Merck Sharp & Dohme LLC Jul 28, 2021 Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Afuresertib Phase 3 Active, not recruiting Laekna Limited Apr 20, 2021 MK-7075 (Miransertib) in Proteus Syndrome Miransertib Phase 2 Active, not recruiting National Human Genome Research Institute (NHGRI) Mar 20, 2020 Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Uprosertib Phase 2 Active, not recruiting National Cancer Institute (NCI) Nov 8, 2013 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer MK-2206 Phase 1 Active, not recruiting National Cancer Institute (NCI) Nov 28, 2011 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer MK-2206 Phase 2 Recruiting QuantumLeap Healthcare Collaborative Jan 5, 2010
Show all 22Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111353 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-22. ChEMBL and Open Targets